Let’s be candid. The era of the single-modality blockbuster, the “one-pill-fits-all” small molecule or the “one-target” monoclonal antibody, is drawing […]
Mastering the New Rules of Small Molecule-Biologic Combination Patents Read Post »
The Multi-Trillion-Dollar Pivot Welcome to the new battlefield. If you are an IP strategist, a business development leader, or an
The New Biologic Gold Rush: Patent Strategy in the Age of Amgen v. Sanofi Read Post »
Introduction: The High-Stakes Game of Pharmaceutical Lifecycles The lifecycle of a drug is a story of immense investment, groundbreaking science,
The intellectual property landscape for small molecule pharmaceuticals has never been more challenging or critical. As R&D costs soar and
Patenting Strategies for Small Molecule Drugs to Maximize ROI and Market Exclusivity Read Post »
For too long, Africa has been viewed through a monolithic lens—a single, challenging market characterized more by risk than by
Redefining Pharmaceutical Portfolio Management The management of a pharmaceutical Research and Development (R&D) portfolio is not a mere administrative function;
The Second Act: Mastering Branded and Generic Drug Portfolio Transformation Read Post »
At its core, the patent system represents a grand bargain between innovator and society. In exchange for disclosing an invention,
The Thicket Maze: A Strategic Guide to Navigating and Dismantling Drug Patent Fortresses Read Post »
In pharmaceutical development the traditional patent term is merely the opening act. The real, value-defining narrative unfolds in the years
The coming patent cliff is already acting as a primary catalyst for industry consolidation. The sheer magnitude of the revenue
A C-Suite Playbook for Navigating the Pharmaceutical Patent Cliff Read Post »
Get fresh news and insights, drug patent expirations & more…
